Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial.
Huimin Lv(Zhengzhou University), Yajing Feng(Zhengzhou University), Limin Niu(Zhengzhou University), Xinlan Liu(Yunnan Agricultural University), Tao Sun(Liaoning Cancer Hospital & Institute), Huihui Sun(Zhengzhou University), Xiaoling Ling(First Hospital of Lanzhou University), Jing Wang(Zhengzhou University), Shumin Chen, Shengnan Zhao(Zhengzhou University), Jin Yang(First Affiliated Hospital of Xi'an Jiaotong University), Mengwei Zhang(Jiangnan University), Min Yan(Shanxi Agricultural University), Huiai Zeng(Zhengzhou University)
Cited by 3
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|743
Chronic obstructive pulmonary disease in China: a nationwide prevalence study
|The Lancet Respiratory Medicine|2018|490
Induction of Pyroptosis and Its Implications in Cancer Management
|Frontiers in Oncology|2019|274